On this page
- Prevention of meningitis due to meningococci groups A, C and W135:
- in mass immunisation campaigns in the event of an outbreak due to meningococcus A, C or W135
- in travellers spending more than 1 month in hyperendemic areas
Composition, forms, route of administration
- Inactivated bacterial vaccine, polysaccharide
- Powder for injection in multidose vial, to be dissolved with the entire vial of the diluent supplied by the manufacturer, for SC injection only
Dosage and vaccination schedule
- Child from 2 years and adult: 0.5 ml single dose
Contra-indications, adverse effects, precautions
- Do not administer to patients with history of an allergic reaction to a previous injection of meningococcal vaccine.
- Vaccination should be postponed in the event of severe acute febrile illness; minor infections are not contra-indications.
- May cause: mild local reaction, mild fever.
- Do not mix with other vaccines in the same syringe (inactivation of vaccines).
- If administered simultaneously with EPI vaccines, use different syringes and injection sites.
- Pregnancy: no contra-indication
- Breast-feeding: no contra-indication
- Immunity develops 7 to 10 days after injection, and lasts for approximately 3 years.
- Powder: between 2 °C and 8 °C.
- Diluent: a cold chain is not required for storage. However, at least 12 hours before reconstitution of the vaccine, the diluent must be refrigerated between 2 °C and 8 °C so that the diluent and lyophilised powder are at the same temperature: a temperature difference during reconstitution may reduce vaccine efficacy. Do not freeze.
- Reconstituted vaccine: between 2 °C and 8 °C, for 6 hours maximum.